Drug Trial Radar · NCT05021536
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
664
Actual
Start
Oct 28, 2021
Primary completion
Jan 19, 2024
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
PlaceboOther
Matching Placebo Comparator
AMX0035Drug
Proprietary formulation of taurursodiol and sodium phenylbutyrate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope ChangeTime frame: 48 weeks
Locations
69 sites in 12 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
University of Southern California
Los Angeles, California
University of California Irvine
Orange, California
California Pacific Medical Center Research Institute
San Francisco, California
University of Colorado
Aurora, Colorado
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
Emory University
Atlanta, Georgia
Augusta University Neuroscience Center
Augusta, Georgia
Northwestern University
Chicago, Illinois
Johns Hopkins University School of Medicine Outpatient Center
Baltimore, Maryland
Healey & AMG Center for ALS Research at Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts
Worcester, Massachusetts
Hennepin Healthcare Research Institute
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Somnos Clinical Research
Lincoln, Nebraska
Rutgers University
New Brunswick, New Jersey
Columbia University
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
The Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania
Austin Neuromuscular Center
Austin, Texas
Texas Neurology
Dallas, Texas
Virginia Commonwealth University
Henrico, Virginia
Swedish Neuroscience Institute
Seattle, Washington
University of Washington
Seattle, Washington
University Hospitals Leuven
Leuven, Belgium
Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC)
Bron, France
Hopital Gabriel Montpied Service de Neurologie
Clermont-Ferrand, France
CHRU de Lille - Hôpital Roger Salengro
Lille, France
CHU de Limoges - Hôpital Dupuytren
Limoges, France
Hôpitaux Universitaires de Marseille Timone
Marseille, France
CHU de Montpellier
Montpellier, France
CHU Nice
Nice, France
Hôpital de la Salpêtrière
Paris, France
Le Centre Hospitalier Régional Universitaire de Tours
Tours, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Uniklinikum Dresden
Dresden, Germany
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.